<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Neuro Farmacologia</title>
	<atom:link href="http://www.neurofarmacologia.net/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.neurofarmacologia.net</link>
	<description></description>
	<lastBuildDate>Tue, 27 Jul 2010 08:11:45 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0</generator>
		<item>
		<title>La sindrome serotoninergica, un approccio pratico</title>
		<link>http://www.neurofarmacologia.net/2010/07/26/la-sindrome-serotoninergica-un-approccio-pratico-alla-diagnosi-e-al-trattamento/</link>
		<comments>http://www.neurofarmacologia.net/2010/07/26/la-sindrome-serotoninergica-un-approccio-pratico-alla-diagnosi-e-al-trattamento/#comments</comments>
		<pubDate>Mon, 26 Jul 2010 11:42:17 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[la mente ed il suo cervello]]></category>
		<category><![CDATA[5HT]]></category>
		<category><![CDATA[citalopram]]></category>
		<category><![CDATA[disturbi d'ansia]]></category>
		<category><![CDATA[effetti collaterali]]></category>
		<category><![CDATA[effetti indesiderati]]></category>
		<category><![CDATA[escitalopram]]></category>
		<category><![CDATA[eventi avversi]]></category>
		<category><![CDATA[fluoxetina]]></category>
		<category><![CDATA[fluvoxamina]]></category>
		<category><![CDATA[Imao]]></category>
		<category><![CDATA[inibitori monoamino ossidasi]]></category>
		<category><![CDATA[iperico]]></category>
		<category><![CDATA[paroxetina]]></category>
		<category><![CDATA[serotonina]]></category>
		<category><![CDATA[sertralina]]></category>
		<category><![CDATA[sindrome serotoninergica]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[tossicità]]></category>
		<category><![CDATA[triptofano]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=1006</guid>
		<description><![CDATA[Con l’introduzione di un numero sempre maggior di farmaci che agiscono attraverso il sistema serotoninergico cerebrale la tossicità da serotonina è diventato un evento avverso di crescente importanza. Molti farmaci sono stati chiamati in causa nella fisiopatologia della sindrome serotoninergica tra cui gli inibitori della ricaptazione della serotonina (SSRIs) . Per evitare fraintendimenti è fondamentale [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/07/26/la-sindrome-serotoninergica-un-approccio-pratico-alla-diagnosi-e-al-trattamento/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Il colloquio psichiatrico</title>
		<link>http://www.neurofarmacologia.net/2010/07/15/il-colloqui-psichiatrico/</link>
		<comments>http://www.neurofarmacologia.net/2010/07/15/il-colloqui-psichiatrico/#comments</comments>
		<pubDate>Thu, 15 Jul 2010 07:49:12 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[i disturbi del comportamento]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[psicopatologia]]></category>
		<category><![CDATA[video]]></category>
		<category><![CDATA[colloquio psichiatrico]]></category>
		<category><![CDATA[educazione continua in medicina]]></category>
		<category><![CDATA[informazione]]></category>
		<category><![CDATA[medicina]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=998</guid>
		<description><![CDATA[In questo video il Professor Di Fiorino descrive il colloquio psichiatrico]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/07/15/il-colloqui-psichiatrico/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Bridging Eastern and western psychiatry: Kiev 2010, una scelta degli argomenti</title>
		<link>http://www.neurofarmacologia.net/2010/06/28/bridging-eastern-and-western-psychiatry-kiev-2010-una-scelta-degli-argomenti/</link>
		<comments>http://www.neurofarmacologia.net/2010/06/28/bridging-eastern-and-western-psychiatry-kiev-2010-una-scelta-degli-argomenti/#comments</comments>
		<pubDate>Mon, 28 Jun 2010 12:47:28 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[English Text]]></category>
		<category><![CDATA[convegni]]></category>
		<category><![CDATA[disturbi dell'umore]]></category>
		<category><![CDATA[disturbi della condotta alimentare]]></category>
		<category><![CDATA[2010]]></category>
		<category><![CDATA[bipolar disorders]]></category>
		<category><![CDATA[congresso]]></category>
		<category><![CDATA[Eating Disorders]]></category>
		<category><![CDATA[kiev presentations]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=985</guid>
		<description><![CDATA[Riportiamo una selezione delle presentazioni proposte al congresso di Kiev 2010 psychometric evaluation of Eating Disorders fluoxetine1 and beyond, Kiev Personality and Temperament in Bipolar Disorders Residential Treatment for Eating Disorders]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/06/28/bridging-eastern-and-western-psychiatry-kiev-2010-una-scelta-degli-argomenti/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Bridging Eastern and Western psychiatry, Kiev 2010</title>
		<link>http://www.neurofarmacologia.net/2010/06/24/bridging-eastern-and-western-psychiatry-kiev-2010/</link>
		<comments>http://www.neurofarmacologia.net/2010/06/24/bridging-eastern-and-western-psychiatry-kiev-2010/#comments</comments>
		<pubDate>Thu, 24 Jun 2010 20:18:57 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[convegni]]></category>
		<category><![CDATA[bridging]]></category>
		<category><![CDATA[congresso]]></category>
		<category><![CDATA[kiev 2010]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=978</guid>
		<description><![CDATA[Le prime immagini del congresso su facebook http://www.facebook.com/home.php?#!/group.php?gid=44407953699&#38;v=wall&#38;ref=mf]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/06/24/bridging-eastern-and-western-psychiatry-kiev-2010/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Da neurolettici ad antidepressivi, le nuove indicazioni degli antipsicotici</title>
		<link>http://www.neurofarmacologia.net/2010/06/07/da-neurolettici-ad-antidepressivi-le-nuove-indicazioni-degli-antipsicotici/</link>
		<comments>http://www.neurofarmacologia.net/2010/06/07/da-neurolettici-ad-antidepressivi-le-nuove-indicazioni-degli-antipsicotici/#comments</comments>
		<pubDate>Mon, 07 Jun 2010 10:53:49 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[disturbi dell'umore]]></category>
		<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[i disturbi del comportamento]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[le psicosi]]></category>
		<category><![CDATA[neuroscienze]]></category>
		<category><![CDATA[abilify]]></category>
		<category><![CDATA[allucinazioni]]></category>
		<category><![CDATA[aloperidolo]]></category>
		<category><![CDATA[antipsicotici]]></category>
		<category><![CDATA[aripiprazolo]]></category>
		<category><![CDATA[atipici]]></category>
		<category><![CDATA[benessere]]></category>
		<category><![CDATA[bipolare]]></category>
		<category><![CDATA[cloropromazina]]></category>
		<category><![CDATA[deliri]]></category>
		<category><![CDATA[depressione]]></category>
		<category><![CDATA[depressione bipolare]]></category>
		<category><![CDATA[dopamina]]></category>
		<category><![CDATA[effetti collaterali]]></category>
		<category><![CDATA[efficacia]]></category>
		<category><![CDATA[farmaci]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[fluoxetina]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[haldol]]></category>
		<category><![CDATA[lamictal]]></category>
		<category><![CDATA[lamotrigina]]></category>
		<category><![CDATA[largactil]]></category>
		<category><![CDATA[mania]]></category>
		<category><![CDATA[monoamine]]></category>
		<category><![CDATA[neurotrasmettitori]]></category>
		<category><![CDATA[noradrenalina]]></category>
		<category><![CDATA[olanzapina]]></category>
		<category><![CDATA[Prozac]]></category>
		<category><![CDATA[psicosi]]></category>
		<category><![CDATA[quetiapina]]></category>
		<category><![CDATA[risperdal]]></category>
		<category><![CDATA[risperidone]]></category>
		<category><![CDATA[salute]]></category>
		<category><![CDATA[sedativi]]></category>
		<category><![CDATA[serenase]]></category>
		<category><![CDATA[seroquel]]></category>
		<category><![CDATA[serotonina]]></category>
		<category><![CDATA[tipici]]></category>
		<category><![CDATA[tollerabilità]]></category>
		<category><![CDATA[zeldox]]></category>
		<category><![CDATA[ziprasidone]]></category>
		<category><![CDATA[zyprexa]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=973</guid>
		<description><![CDATA[L’utilizzo di farmaci antipsicotici nel trattamento delle varie forme di disturbo bipolare non è certo una novità. Le forme più gravi di eccitamento maniacale venivano trattate con antipsicotici di prima generazione fin dagli anni ’70. La storia dei farmaci antipsicotici tuttavia comincia con le molecole di prima generazione (antipsicotici tipici o neurolettici) nel 1952, quando [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/06/07/da-neurolettici-ad-antidepressivi-le-nuove-indicazioni-degli-antipsicotici/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Disturbo D&#8217;Ansia Generalizzata</title>
		<link>http://www.neurofarmacologia.net/2010/05/21/disturbo-dansia-generalizzata/</link>
		<comments>http://www.neurofarmacologia.net/2010/05/21/disturbo-dansia-generalizzata/#comments</comments>
		<pubDate>Fri, 21 May 2010 08:24:25 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[disturbi d'ansia]]></category>
		<category><![CDATA[i disturbi del comportamento]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[la mente ed il suo cervello]]></category>
		<category><![CDATA[neuroscienze]]></category>
		<category><![CDATA[ansia generalizzata]]></category>
		<category><![CDATA[ansiolitici]]></category>
		<category><![CDATA[anticonvulsivanti]]></category>
		<category><![CDATA[antidepressivi]]></category>
		<category><![CDATA[benzodiazepine]]></category>
		<category><![CDATA[cognitivo]]></category>
		<category><![CDATA[complicanze]]></category>
		<category><![CDATA[comportamentale]]></category>
		<category><![CDATA[criteri diagnostici]]></category>
		<category><![CDATA[dag]]></category>
		<category><![CDATA[diagnosi]]></category>
		<category><![CDATA[diagnosi differenziale]]></category>
		<category><![CDATA[disturbo]]></category>
		<category><![CDATA[DSM]]></category>
		<category><![CDATA[farmaci]]></category>
		<category><![CDATA[gad]]></category>
		<category><![CDATA[manauale diagnostico e statistico malattie mentali]]></category>
		<category><![CDATA[neurotrasmettitori]]></category>
		<category><![CDATA[neurovegetativi]]></category>
		<category><![CDATA[psichiatria]]></category>
		<category><![CDATA[psicoterapia]]></category>
		<category><![CDATA[sintomi psichici]]></category>
		<category><![CDATA[tensione]]></category>
		<category><![CDATA[trattamento]]></category>
		<category><![CDATA[trattamento farmacologico]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=968</guid>
		<description><![CDATA[Ricevo e volentieri pubblico il lavoro del collega Claudio Cargioli, medico chirurgo presso la scuola di specializzazione in psichiatria dell&#8217;università di Pisa. Per informazioni o contatti claudiocargioli@gmail.com Il Disturbo d’Ansia Generalizzata (GAD) Il GAD rappresenta un comune disturbo psichiatrico, con una prevalenza dal 3 all’8% nella popolazione generale, un frequente esordio in età giovanile ed [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/05/21/disturbo-dansia-generalizzata/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Bridging Eastern adn Western Psychiatry, kiev 2010</title>
		<link>http://www.neurofarmacologia.net/2010/05/04/bridging-eastern-adn-western-psychiatry-kiev-2010/</link>
		<comments>http://www.neurofarmacologia.net/2010/05/04/bridging-eastern-adn-western-psychiatry-kiev-2010/#comments</comments>
		<pubDate>Tue, 04 May 2010 08:56:41 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[psicofarmacobufale]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=954</guid>
		<description><![CDATA[  13th conference of Bridging Eastern   and Western Psychiatry Kyiv (Ukraine) June 10th-13th 2010 Coping complex issues for Contemporary Psychiatry: What we can treat; what we cannot treat Scientific Secretariat Alessandro Del Debbio:  E mail: adeldebbio@gmail.com Jacopo G. Massei  E mail:  j_massei@virgilio.it Web site  http://www.psyter.net Hotel accomodation We have reserved rooms at special rates in selected [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/05/04/bridging-eastern-adn-western-psychiatry-kiev-2010/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Agomelatina, un nuovo antidepressivo</title>
		<link>http://www.neurofarmacologia.net/2010/04/26/agomelatina-un-nuovo-antidepressivo/</link>
		<comments>http://www.neurofarmacologia.net/2010/04/26/agomelatina-un-nuovo-antidepressivo/#comments</comments>
		<pubDate>Mon, 26 Apr 2010 11:34:20 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[disturbi d'ansia]]></category>
		<category><![CDATA[disturbi dell'umore]]></category>
		<category><![CDATA[farmacologia clinica]]></category>
		<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[agomelatina]]></category>
		<category><![CDATA[ansia]]></category>
		<category><![CDATA[attenzione]]></category>
		<category><![CDATA[dopamina]]></category>
		<category><![CDATA[efficacia]]></category>
		<category><![CDATA[escitalopram]]></category>
		<category><![CDATA[meccanismo antidepressivo]]></category>
		<category><![CDATA[melatonina]]></category>
		<category><![CDATA[noradrenalina]]></category>
		<category><![CDATA[sertralina]]></category>
		<category><![CDATA[sonno]]></category>
		<category><![CDATA[tollerabilità]]></category>
		<category><![CDATA[umore]]></category>
		<category><![CDATA[venlafaxina]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=946</guid>
		<description><![CDATA[La melatonina, una sostanza normalmente prodotta dalla nostra ghiandola pineale, agisce nel nostro corpo come una sorta di sincronizzatore dei ritmi biologici e la sua secrezione è strettamente correlata con l&#8217;alternanza del giorno e della notte e delle stagioni. Le capacità della melatonina di regolarizzare il ritmo sonno veglia e di agire sul tono dell&#8217;umore [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/04/26/agomelatina-un-nuovo-antidepressivo/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>I neuroni specchio, modelli comportamentali ed ipotesi funzionali</title>
		<link>http://www.neurofarmacologia.net/2010/04/13/i-neuroni-specchio-modelli-comportamentali-ed-ipotesi-funzionali/</link>
		<comments>http://www.neurofarmacologia.net/2010/04/13/i-neuroni-specchio-modelli-comportamentali-ed-ipotesi-funzionali/#comments</comments>
		<pubDate>Tue, 13 Apr 2010 17:59:12 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[la mente ed il suo cervello]]></category>
		<category><![CDATA[neuroscienze]]></category>
		<category><![CDATA[comportamento]]></category>
		<category><![CDATA[esperimenti]]></category>
		<category><![CDATA[ipotesi funzionali]]></category>
		<category><![CDATA[mirror neurons]]></category>
		<category><![CDATA[modelli animali]]></category>
		<category><![CDATA[modelli mente]]></category>
		<category><![CDATA[neuroni specchio]]></category>
		<category><![CDATA[spiegazione]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=938</guid>
		<description><![CDATA[I neuroni specchio (mirror neurons) sono una classe di neuroni che si attivano selettivamente sia quando si compie un&#8217;azione, sia quando si osserva una azione mentre è compiuta da altri. I neuroni dell&#8217;osservatore &#8220;rispecchiano&#8221; ciò che avviene nella mente del soggetto osservato, come se fosse l&#8217;osservatore stesso a compiere l&#8217;azione. Questa classe di neuroni è [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/04/13/i-neuroni-specchio-modelli-comportamentali-ed-ipotesi-funzionali/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Brevetti sui geni umani</title>
		<link>http://www.neurofarmacologia.net/2010/03/31/brevetti-sui-geni-umani/</link>
		<comments>http://www.neurofarmacologia.net/2010/03/31/brevetti-sui-geni-umani/#comments</comments>
		<pubDate>Wed, 31 Mar 2010 08:58:50 +0000</pubDate>
		<dc:creator>Bruno Pacciardi</dc:creator>
				<category><![CDATA[informazione medica]]></category>
		<category><![CDATA[neuroscienze]]></category>
		<category><![CDATA[BRCA1]]></category>
		<category><![CDATA[BRCA2]]></category>
		<category><![CDATA[brevetti]]></category>
		<category><![CDATA[corte suprema]]></category>
		<category><![CDATA[fenomeni naturali]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[geni]]></category>
		<category><![CDATA[geni umani]]></category>
		<category><![CDATA[genoma]]></category>
		<category><![CDATA[giudice]]></category>
		<category><![CDATA[interessi industria]]></category>
		<category><![CDATA[mappatura]]></category>
		<category><![CDATA[monopolio]]></category>
		<category><![CDATA[proprietà]]></category>
		<category><![CDATA[robert sweet]]></category>
		<category><![CDATA[sentenza]]></category>
		<category><![CDATA[terapie geniche]]></category>
		<category><![CDATA[test]]></category>
		<category><![CDATA[tribunale federale]]></category>
		<category><![CDATA[umano]]></category>

		<guid isPermaLink="false">http://www.neurofarmacologia.net/?p=935</guid>
		<description><![CDATA[Un recente articolo sul &#8220;The Economist&#8221; porta all&#8217;attenzione del grande pubblico una spinosa questione: il problema dell&#8217;interesse dell&#8217;industria in ambito scientifico. Gli sviluppi della medicina basata sulla genetica hanno consentito, oltre alla decodifica del genoma umano, la messa a punto dei primi test basati sulla mappatura del gene. Il caso specifico riportato è quello di [...]]]></description>
		<wfw:commentRss>http://www.neurofarmacologia.net/2010/03/31/brevetti-sui-geni-umani/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>
